Pancreatic Cancer Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Ther

The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.

DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Cancer Market Forecast
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pancreatic Cancer Market Report:
• The Pancreatic Cancer market size was valued approximately and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, Swedish immunotherapy firm Anocca has received regulatory clearance in four European countries to initiate its Phase I/II VIDAR-1 clinical trial. This study will focus on patients with advanced pancreatic cancer that is positive for the KRAS gene. The trial will start by assessing ANOC-001, Anocca's lead candidate, which specifically targets the KRAS G12V mutation, where glycine at position 12 is replaced by valine.
• In December 2024, Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) compared to the control. The PANOVA-3 trial assessed the use of Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
• According to DelveInsight's estimates, the total incident cases of pancreatic cancer in the United States accounted for approximately 35% in 2023.
• The 2023 analysis indicates that the highest stage-specific incident cases of pancreatic cancer in the US were for distant stages, comprising nearly 50% of cases, followed by regional and localized stages.
• The mutation types associated with pancreatic cancer include KRAS2, TP53, SMAD4/DPC4, BRCA1/2, MSI-H/dMMR, and NTRK. In the United States, KRAS2 and TP53 were responsible for the largest number of incident cases of pancreatic cancer in 2023.
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
• The Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Cancer than females

Request a sample for the Pancreatic Cancer Market Report:
https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Cancer Overview
Pancreatic adenocarcinoma is one of the most aggressive forms of cancer and is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States in the near future. In the US, pancreatic cancer is the 9th or 10th most commonly diagnosed cancer (depending on gender). A clinical/radiographic stage classification for pancreatic cancer suggests three stage classification(potentially resectable, locally advanced, and advanced) of pancreatic cancer involvement based on radiological findings.
Localized pancreatic cancer is the one that remains confined to its location of origin and does not spreads out. Surgery remains the only option for these kinds of cancer cells. • Locally advanced Pancreatic Cancer is a non-metastasized pancreatic cancer, in which upfront resection is considered not beneficial due to extensive vascular involvement and the consequent high chance of a nonradical resection. These patients have significant symptom burdens referable to their primary malignancy, including pain (usually in the abdomen or back), pancreatic insufficiency, biliary obstruction, and early satiety/gastric outlet obstruction, weight loss, jaundice (yellowing of the skin, eyes or both)with or without itching, loss of appetite, nausea, change in stool, pancreatitis, recent-onset diabetes.

Pancreatic Cancer Epidemiology Segmentation:
The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Pancreatic Cancer
• Prevalent Cases of Pancreatic Cancer by severity
• Gender-specific Prevalence of Pancreatic Cancer
• Diagnosed Cases of Episodic and Chronic Pancreatic Cancer

Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Cancer Market
The dynamics of the Pancreatic Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Niraparib, Dostarlimab, and others during the forecasted period 2020-2034.

Pancreatic Cancer Therapies and Key Companies
• LYNPARZA (olaparib): AstraZeneca
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• Elraglusib (9 ING 41): Actuate Therapeutics
• DF 7001: Dragonfly Therapeutics CMG 901 Keymed B
• TNG260: Tango Therapeutics
• ATA 3271: Atara Biotherapeutics
• CMG 901: Keymed Biosciences Co.Ltd
• CT-0508: Carisma Therapeutics Inc
• CUE-102: Cue Biopharma
• BOLD-100: Bold Therapeutics
• CM24: Purple Biotech Ltd
• ENB-003: ENB Therapeutics
• GRT-C903: Gritstone bio
• AZD0171: AstraZeneca
• CAN-2409: Candel Therapeutics
• Mitazalimab: Alligator Bioscience
• Pamrevlumab: FibroGen
• NIS793: Novartis AG
• Masitinib: AB Science
• Glufosfamide: Eleison Pharmaceuticals

To know more about Pancreatic Cancer treatment, visit @ Pancreatic Cancer Medications
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Cancer Market Drivers
• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Pancreatic Cancer
• Strong pipeline activity

Pancreatic Cancer Market Barriers
• Rising incidence of cancer will provide a larger window of opportunity for new treatments
• Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity

Scope of the Pancreatic Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
• Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies
• Migraine Market Dynamics: Pancreatic Cancer market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Pancreatic Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Pancreatic Cancer market share @ Pancreatic Cancer Treatment Landscape
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pancreatic Cancer Market Report Introduction
2. Executive Summary for Pancreatic Cancer
3. SWOT analysis of Pancreatic Cancer
4. Pancreatic Cancer Patient Share (%) Overview at a Glance
5. Pancreatic Cancer Market Overview at a Glance
6. Pancreatic Cancer Disease Background and Overview
7. Pancreatic Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Pancreatic Cancer
9. Pancreatic Cancer Current Treatment and Medical Practices
10. Pancreatic Cancer Unmet Needs
11. Pancreatic Cancer Emerging Therapies
12. Pancreatic Cancer Market Outlook
13. Country-Wise Pancreatic Cancer Market Analysis (2020-2034)
14. Pancreatic Cancer Market Access and Reimbursement of Therapies
15. Pancreatic Cancer Market drivers
16. Pancreatic Cancer Market barriers
17. Pancreatic Cancer Appendix
18. Pancreatic Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Pancreatic Cancer Pipeline https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Pancreatic Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pancreatic Cancer market. A detailed picture of the Pancreatic Cancer pipeline landscape is provided, which includes the disease overview and Pancreatic Cancer treatment guidelines.

Pancreatic Cancer Epidemiology https://www.delveinsight.com/report-store/pancreatic-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pancreatic Cancer Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Pancreatic Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.